- Short answer: trial averages differ by drug — semaglutide ~12–17% at 68 weeks; tirzepatide often higher (18–25% in SURMOUNT data). Individual results depend on baseline weight, adherence, dose, and lifestyle support.
How much weight will you lose on GLP-1?
Direct answer: averages vary by drug and dose — semaglutide trials report roughly 12–17% average loss at 68 weeks; tirzepatide trials report higher averages (often 18–25% at similar timelines).
Why aren’t trial averages your guarantee?
Direct answer: trials enroll selected populations, provide close follow-up, and enforce adherence; real-world results are often lower because of dose changes, side effects, and less structured support.
What timeline should you expect?
Direct answer: most weight is lost in the first 4–9 months as the dose is titrated; the curve flattens after that but continues slowly if adherence remains.
What predicts a stronger response?
Direct answer: higher baseline BMI, greater dose exposure, consistent adherence, and concurrent behavioral support all predict better outcomes. Genetics and metabolic differences also matter.
How should you interpret trial numbers in real life?
Direct answer: convert percent-to-pounds for your baseline to set realistic targets. If a trial shows a 15% average loss and you weigh 220 lb, that’s ~33 lb average — a useful reference, not a promise.
When should you adjust expectations or plans?
Direct answer: if you’re not seeing steady progress after 6 months despite adherence, discuss dose strategy, side effects, nutrition, and exercise with your clinician.
Related resources
Citations
- Once-weekly semaglutide (STEP): https://pubmed.ncbi.nlm.nih.gov/33567185/
- SURMOUNT tirzepatide data summary: https://pubmed.ncbi.nlm.nih.gov/36273454/
- Body composition and semaglutide: https://pubmed.ncbi.nlm.nih.gov/36449799/
FTC Disclosure
FTC Disclosure: No affiliate links in this piece at publish time.
Medical Disclaimer
This is educational content only. Discuss expectations with your clinician.